Re-cutting the Investment Rubric When Strategy Moves Under a Live Portfolio
Northbridge Health is a regional insurer running a $180 million, 42-component portfolio. The board's new three-year strategy moves the company from broker-led sales to direct digital self-service and targets an expense-ratio reduction from 24% to 19%. The portfolio office still scores business cases on a 2019 rubric weighted 40% toward premium growth through intermediaries. Two symptoms are already visible. A $34 million core mainframe modernization - 19% of portfolio budget - carries a benefits case built almost entirely on broker commission savings that the new strategy is designed to eliminate. Separately, a broker portal sponsored by the chief distribution officer was approved two months after the strategy launch, with the stated benefit "protect broker relationships." Meanwhile the digital identity and payments platform that direct sales depends on is funded at 60% of requested scope and slipping. The investment committee meets in three weeks. The CFO has asked the portfolio manager to "bring the portfolio in line" but has not said what that means for contracts already signed.
1. The investment committee wants a defensible way to realign selection with the new strategy without invalidating everything in flight. What should the portfolio manager propose, and what evidence must exist before the next committee?
Read the worked answer
The rubric is the actual problem, not the projects. A 40% weighting on intermediary-driven premium growth is a proxy for a strategy the board has retired, so every downstream score is contaminated. Re-weighting it is necessary but insufficient - sponsors will simply re-label benefits to fit new words.
Proposal to the committee:
- Re-derive criteria from the published strategy map, not from last year's rubric: direct-channel acquisition cost, digital adoption rate, expense-ratio contribution, and regulatory obligation. Keep a scored strategic-fit dimension owned by the strategy office, not by the sponsoring executive.
- Require each component to state a falsifiable benefit hypothesis with a named business benefit owner and a measured baseline. "Protect broker relationships" fails this test as written; it has no metric, no baseline, and no owner outside the sponsor.
- Re-score all 42 components with one panel using the new rubric, then triage into four explicit buckets: continue, reshape, pause, exit. Publish the triage, because silence lets sponsors lobby individually.
Evidence needed in three weeks: not a full re-appraisal, but a re-score of the in-flight and gate-pending components, the dependency map showing that direct sales depends on the underfunded identity platform, and a costed exception log for anything that cannot be re-scored in time. The committee should also see capacity by skill, since a strategy change that reallocates money without reallocating scarce engineers produces a paper realignment only.
2. What should the portfolio manager recommend for the $34 million mainframe modernization, which is mid-execution with committed contracts?
Read the worked answer
Separate two questions that sponsors habitually merge: is the remaining work still strategically justified, and is the original benefits claim still valid? The benefits case is clearly broken. That alone does not prove the work is wrong - mainframe scope often includes regulatory compliance, capacity for digital transaction growth, and run-cost reduction that survives the strategy shift.
Recommendation: a 30-day reshape-or-exit options analysis, with non-essential scope stopped immediately. Three options should be costed:
- Continue as scoped - defensible only if the remaining deliverables map to direct-channel economics or a regulatory obligation.
- Reshape - retain the compliance and capacity enablers, de-scope broker-commission-dependent elements, re-baseline benefits with a new owner, and renegotiate rather than terminate contracts. Preserves the team and avoids termination penalties.
- Exit - quantify termination cost, notice periods, and the value of redeploying $34 million and the associated engineers to the identity platform. Sunk cost is irrelevant; termination cost is a real constraint and must appear in the paper.
The decision belongs to the investment committee, not the sponsor, because it reallocates capacity across components. Whatever the outcome, record the benefits shortfall explicitly - a project can succeed technically and still fail as an investment, and the portfolio record must say so.
3. How should the portfolio manager handle the chief distribution officer who sponsored the broker portal after the strategy launch?
Read the worked answer
Treat this as a relationship and process problem, not a compliance problem. The sponsor's underlying concern - erosion of the broker channel - is legitimate and may be underweighted in the new strategy; a public fight in committee will harden resistance and produce workarounds.
Sequence:
- Privately share the re-scored assessment and the strategy map before the committee meets. The goal is that the sponsor learns the score from the portfolio manager, not as an ambush.
- Ask what evidence would change the sponsor's mind, and offer a capped proof-of-value: a small funded discovery with a defined question (for example, measured broker retention impact of digital servicing), a fixed budget, and a stage gate. This converts an ideological dispute into an empirical one and gives the sponsor a face-saving path.
- If the portal is confirmed as misaligned, recommend pause - not cancellation - pending the discovery result, and document the dissent in the decision record. Recorded dissent protects the sponsor and the portfolio.
Escalate only if the sponsor bypasses the committee or funds work outside the portfolio process. Escalating a disagreement before it has been tested is a failure of the portfolio manager's pre-wiring role.